MARKET

MEOBF

MEOBF

Mesoblast
OTCPK
1.700
NaN%
Closed 09:30 05/20 EDT
OPEN
--
PREV CLOSE
1.700
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
1.900
52 WEEK LOW
0.965
MARKET CAP
2.20B
P/E (TTM)
-23.0665
1D
5D
1M
3M
1Y
5Y
1D
Largest borrow rate increases among liquid names
TipRanks · 05/13 15:20
Bell Potter Sticks to Their Buy Rating for Mesoblast Limited (MEOBF)
TipRanks · 05/01 01:05
Mesoblast Ramps Up Ryoncil Sales, Advances Late-Stage Cell Therapy Pipeline
TipRanks · 04/30 01:45
Mesoblast Hits Phase 3 Recruitment Milestone in Chronic Back Pain Push
TipRanks · 04/29 00:44
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
Barchart · 04/28 19:53
Mesoblast Director Boosts Indirect Stake in Multimillion-Dollar Share Purchase
TipRanks · 04/16 08:33
Mesoblast Reports Lapse of 723,666 Options, Reducing Potential Dilution
TipRanks · 04/16 08:16
Mesoblast Issues 3.28 Million New Shares on Option Conversions
TipRanks · 04/16 08:15
More
About MEOBF
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd stock information, including OTCPK: MEOBF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEOBF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MEOBF stock methods without spending real money on the virtual paper trading platform.